...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular physiology. >Network-based analysis reveals novel gene signatures in the peripheral blood of patients with sporadic nonsyndromic thoracic aortic aneurysm
【24h】

Network-based analysis reveals novel gene signatures in the peripheral blood of patients with sporadic nonsyndromic thoracic aortic aneurysm

机译：基于网络的分析揭示了小说的基因患者外周血的签名零星nonsyndromic胸主动脉动脉瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Thoracic aortic aneurysm (TAA), a serious cardiovascular disease that causes morbidity and mortality worldwide. At present, few biomarkers can accurately diagnose the appearance of TAA before dissection or rupture. Our research has the intention to investigate the developing applicable biomarkers for TAA promising clinically diagnostic biomarkers or probable regulatory targets for TAA. In our research, we built correlation networks utilizing the expression profile of peripheral blood mononuclear cell obtained from a public microarray data set (GSE9106). Furthermore, we chose the turquoise module, which has the strongest significance with TAA and was further analyzed. Fourteen genes that overlapped with differentially expressed proteins in the medial aortic layer were obtained. Subsequently, we verified the results applying quantitative polymerase chain reaction (Q-PCR) to our clinical specimen. In general, the Q-PCR results coincide with the majority of the expression profile. Fascinatingly, a notable change occurred in CLU, DES, MYH10, and FBLN5. In summary, using weighted gene coexpression analysis, our study indicates that CLU, DES, MYH10, and FBLN5 were identified and validated to be related to TAA and might be candidate biomarkers or therapeutic targets for TAA.
机译：胸主动脉瘤(TAA)、严重导致的发病率和心血管疾病全球死亡率。可以准确地诊断TAA的外观吗在解剖或破裂。目的探讨发展适用的TAA有前途的生物标志物临床诊断生物标记或可能的TAA的监管目标。建立相关网络利用外周血的表达谱单核细胞从公共获取微阵列数据集(GSE9106)。选择了绿松石模块,最强的TAA和进一步的意义分析。差异表达的蛋白质在内侧主动脉层。应用定量验证结果聚合酶链反应(Q-PCR)临床标本。与大多数的表达谱。迷人地,一个显著的变化发生在健身房,DES, MYH10 FBLN5。基因coexpression分析,我们的研究表明CLU, DES, MYH10 FBLN5被确定和验证有关TAA和可能候选人生物标志物或治疗的目标

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号